652 (1987); PCT Publication No. WO 88/09810, published December 15, 1988) or blood-brain barrier (see, *e.g.*, PCT Publication No. WO 89/10134, published April 25, 1988), hybridization-triggered cleavage agents (see, *e.g.*, Van Der Krol et al., *BioTechniques* 6:958-976 (1988)) or intercalating agents (see, *e.g.*, Zon, *Pharm. Res.* 5:539-549 (1988)).

Please replace the paragraph on page 165, lines 5-13, with the following:

Overexpression of the gene product was achieved in *E. coli* strain BL21(DE3) (Novagen, Madison WI) containing the DNAY plasmid for rare codon optimization (see, *e.g.*, Garcia *et al.* (1986) *Cell 45:*.453-459). Cells were grown at 37 °C in (2xYT) media supplemented with carbenicillin and kanamycin to a final concentrations of 50 ug/ml and 34 ug/ml, respectively. One liter cultures were inoculated with 10 mL of an overnight culture grown in the same media. Cells were allowed to grow to a density of 0.6 – 1.0 OD_{600} before the addition of IPTG (final concentration 1.0 mM). Cells were grown an additional 4 hours before harvesting.

IN THE CLAIMS:

Please cancel claim 116 without prejudice or disclaimer.

Please replace claims 2, 27, 28, and 133 with the following amended claims (a marked-up copy of the amended claims is attached to this Amendment):

2. (Amended) The substantially purified polypeptide of claim 1, wherein the MTSP is not expressed on endothelial cells.

27. (Amended) The cell of claim 25 that is a eukaryotic cell.

28. (Amended) The cell of claim 25 that is selected from among a bacterial cell, a yeast cell, a plant cell, an insect cell and an animal cell.

133. (Amended) A method of detecting neoplastic disease, comprising: detecting an MTSP3, MTSP4 or MTSP6 of claim 90 in a biological sample, wherein the amount detected differs from the amount in a subject who does not have neoplastic disease.